While there is currently no research specifically examining the interaction of empagliflozin with TYMS and PTGS2, these molecules represent potential therapeutic targets for managing NAFLD and NAFLD-related AF. This evidence concerns the gene TYMS and metabolic dysfunction-associated steatotic liver disease.